MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ibra.70016

Медицинская библиотека · Ibrain · 2026

Preclinical advances in antibodies against N-terminal Aβ4-x species for Alzheimer's disease and cerebral amyloid angiopathy.

Valle Maria Luisa, Arienzo Donatello

СтатьяОбзорПеревод пока не подготовлен

Аннотация

Alzheimer's disease (AD) pathogenesis is characterized by the accumulation of amyloid beta (Aβ) deposits in the cerebral parenchyma and vasculature, a condition referred to as cerebral amyloid angiopathy (CAA). Besides the full-length form, Aβ deposits showed a highly heterogenous composition due to the action of different proteolytic enzymes. N-terminal Aβ peptides have shown higher aggregation propensity and toxicity compared to the other truncated forms, with species starting at residue phenylalanine 4 (Aβ4-x) being more neurotoxic than the others. Thus, Aβ4-x species have drawn attention in AD pathogenesis, potentially offering novel therapeutic targets to halt or reverse disease progression. Antibodies targeting specifically Aβ4-x species were designed with the aim of preventing their aggregation and promoting their clearance counterbalancing their neurotoxic effect. This work provides an update on monoclonal and polyclonal antibodies developed to specifically target Aβ4-x species in AD and CAA preclinical studies (in vitro and in vivo models).

Для цитирования: Valle Maria Luisa, Arienzo Donatello. Preclinical advances in antibodies against N-terminal Aβ4-x species for Alzheimer's disease and cerebral amyloid angiopathy.. Ibrain. 2026. DOI: 10.1002/ibra.70016.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.